Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775684 · ClinicalTrials.gov registry record · NA
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT00775684: Completed NA study, sponsored by University of Pennsylvania.
NCT00775684 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00775684, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study evaluates exenatide, sitagliptin, and glimepiride for the treatment of high blood sugar in patients with impaired fasting glucose or early type 2 diabetes. The purpose of this study is to determine if exenatide and sitagliptin increase the amount of insulin made by the pancreas compared to glimepiride. It is hypothesized that exenatide or sitagliptin will sustain or increase the amount of insulin made by the pancreas in comparison to glimepiride.
Interventions
- DRUG Sitagliptin
- DRUG Exenatide
- DRUG Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00775684
The ClinicalTrials.gov registry entry for NCT00775684 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sitagliptin is the first listed.
NCT00775684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00775684 about?
NCT00775684 is a clinical study titled "Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass". This study evaluates exenatide, sitagliptin, and glimepiride for the treatment of high blood sugar in patients with impaired fasting glucose or early type 2 diabetes. The purpose of this study is to determine if exenatide and sitagliptin increase the amount of insulin made by the pancreas compared t...
What is the current status of trial NCT00775684?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2008-10. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00775684?
The interventions under investigation include: Sitagliptin (DRUG), Exenatide (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT00775684?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.